EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Quest for Non-Invasive Diagnosis: A Review of Liquid Biopsy in Glioblastoma

Maria George Elias iD, Harry Hadjiyiannis, Fatemeh Vafaee iD, Kieran F Scott iD, Paul de Souza, Therese M Becker iD, Shadma Fatima iD

Cancers · 19.08.2025 · 17 (16) · 2700

DOI: 10.3390/cancers17162700 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 19.08.2025. Verfasst von Maria George Elias und 6 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology, Ingham Institute for Applied Medical Research, Liverpool, NSW 2170, Australia. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 189 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumour, associated with poor survival outcomes and significant clinical challenges. Conventional diagnostic methods, including MRI, CT, and histopathological analysis of tissue biopsies, are limited by their inability to reliably distinguish treatment effects from true tumour progression, often resulting in misdiagnosis and delayed intervention. Repeated tissue biopsies are also invasive and unsuitable for longitudinal monitoring. Liquid biopsy, a minimally invasive approach analysing tumour-derived material in biofluids such as blood and cerebrospinal fluid (CSF), offers a promising alternative. This review aims to evaluate current evidence on circulating biomarkers including circulating tumour cells (CTCs), circulating tumour DNA (ctDNA), microRNAs (miRNAs), extracellular vesicles (EVs), and proteins in GBM diagnosis and monitoring, and to assess the potential role of artificial intelligence (AI) in enhancing their clinical application.

Methods

A narrative synthesis of the literature was undertaken, focusing on studies that have investigated blood- and CSF-derived biomarkers in GBM patients. Key aspects evaluated included biomarker biology, detection techniques, diagnostic and prognostic value, current technical challenges, and progress towards clinical translation. Studies exploring AI and machine learning (ML) approaches for biomarker integration and analysis were also reviewed.

Results

Liquid biopsy enables repeated and minimally invasive sampling of tumour-derived material, reflecting the genetic, epigenetic, proteomic, and metabolomic landscape of GBM. Although promising, its translation into routine clinical practice is hindered by the low abundance of circulating biomarkers and lack of standardised collection and analysis protocols. Evidence suggests that combining multiple biomarkers improves sensitivity and specificity compared with single-marker approaches. Emerging AI and ML tools show significant potential for improving biomarker discovery, integrating multi-omic datasets, and enhancing diagnostic and prognostic accuracy.

Conclusions

Liquid biopsy represents a transformative tool for GBM management, with the capacity to overcome limitations of conventional diagnostics and provide real-time insights into tumour biology. By integrating multiple circulating biomarkers and leveraging AI-driven approaches, liquid biopsy could enhance diagnostic precision, enable dynamic disease monitoring, and improve clinical decision-making. However, large-scale validation and standardisation are required before routine clinical adoption can be achieved.

Schlagwörter

Stichwörter der Autor:innen

biomarkersglioblastoma multiformeliquid biopsies

Autor:innen und Institutionen

  • Medical Oncology, Ingham Institute for Applied Medical Research, Liverpool, NSW 2170, Australia.
  • School of Science, Western Sydney University, Locked Bag 1797, Penrith South DC, Sydney, NSW 2751, Australia.
  • School of Medicine, Western Sydney University, Locked Bag 1797, Penrith South DC, Sydney, NSW 2751, Australia.
  • School of Biotechnology and Biomolecular Science, University of New South Wales, Sydney, NSW 2052, Australia.
  • UNSW AI Institute, University of New South Wales, Sydney, NSW 2052, Australia.
  • Nepean Clinical School, The University of Sydney, Sydney, NSW 2747, Australia.

ORCID-Profile: Maria George Elias, Fatemeh Vafaee, Kieran F Scott, Therese M Becker, Shadma Fatima

Zitieren

APA

Elias, M. G., Hadjiyiannis, H., Vafaee, F., Scott, K. F., de Souza, P., Becker, T. M., & Fatima, S. (2025). The Quest for Non-Invasive Diagnosis: A Review of Liquid Biopsy in Glioblastoma. Cancers, 17(16), 2700. https://doi.org/10.3390/cancers17162700

Vancouver

Elias MG, Hadjiyiannis H, Vafaee F, Scott KF, de Souza P, Becker TM, et al. The Quest for Non-Invasive Diagnosis: A Review of Liquid Biopsy in Glioblastoma. Cancers. 2025;17(16):2700. doi:10.3390/cancers17162700

BibTeX
@article{Elias2025,
  author = {Elias, Maria George and Hadjiyiannis, Harry and Vafaee, Fatemeh and Scott, Kieran F and de Souza, Paul and Becker, Therese M and Fatima, Shadma},
  title = {The Quest for Non-Invasive Diagnosis: A Review of Liquid Biopsy in Glioblastoma},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {16},
  pages = {2700},
  doi = {10.3390/cancers17162700}
}
Kostenlos starten →